Table 1 Demographic and clinical characteristics
Variable | Adverse outcomes(n = 283) | Control(n = 573) | p value |
|---|---|---|---|
Age(year) | 66 (58–70) | 61 (53–69) |  < 0.001 |
Gender(male,%) | 174 (61.5) | 329 (57.4) | 0.255 |
BMI(kg/m2) | 23.4 (21.5–25.6) | 23.5 (21.6–25.5) | 0.813 |
Preoperative LVEF (%) | 54 (46–57) | 55(48–57) | 0.191 |
NYHA(n,%) | Â | Â | 0.261 |
 II | 109 (38.5) | 222 (38.7) |  |
 III | 153 (54.1) | 324 (56.5) |  |
 IV | 21 (7.4) | 27 (4.7) |  |
 Previous history of cardiac surgery(n,%) | 30 (10.6) | 44 (7.7) | 0.152 |
Previous medical history(n,%) | |||
 Heart failure | 3 (1.1) | 5 (0.9) | 0.789 |
 Atrial fibrillation | 29 (10.2) | 65 (11.3) | 0.629 |
 Hypertension | 116 (41.0) | 231 (40.3) | 0.850 |
 Diabetes mellitus | 33 (11.7) | 53 (9.2) | 0.270 |
 COPD | 16 (5.7) | 36 (6.3) | 0.717 |
 Chronic liver disease | 6 (2.1) | 10 (1.7) | 0.703 |
 Chronic renal disease | 9 (3.2) | 10 (1.7) | 0.180 |
 Coronary disease | 38 (13.4) | 64 (11.2) | 0.337 |
 Smoking | 29 (10.2) | 43 (7.5) | 0.174 |
 Excessive alcohol | 29 (10.2) | 42 (7.3) | 0.145 |
Medications(n,%) | |||
 Statins | 11 (3.9) | 12 (2.1) | 0.127 |
 Hypoglycemic drug | 31 (11.0) | 51 (8.9) | 0.337 |
 Antiplatelet | 11 (3.9) | 15 (2.6) | 0.309 |
 Anticoagulant | 9 (3.2) | 23 (4.0) | 0.545 |
 Calcium channel blocker | 66 (23.3) | 111 (19.4) | 0.179 |
 ACE inhibitor or ARB | 51 (18.0) | 112 (19.5) | 0.593 |
 Diuretic | 16 (5.7) | 34 (5.9) | 0.869 |
 b-blocker | 29 (10.2) | 56 (9.8) | 0.827 |